Tysabri
E24936
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Tysabri canonical | 6 |
| natalizumab | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T195372 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Tysabri Context triple: [Biogen, hasProduct, Tysabri]
-
A.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
-
D.
Pregny-Chambésy
Pregny-Chambésy is a small, affluent municipality on the shores of Lake Geneva in the canton of Geneva, Switzerland, known for hosting several international organizations and diplomatic missions.
-
E.
BB-37
BB-37 is the hull number of USS Oklahoma, a Nevada-class battleship of the United States Navy that was sunk during the attack on Pearl Harbor in 1941.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Tysabri Target entity description: Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
A.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
-
D.
Pregny-Chambésy
Pregny-Chambésy is a small, affluent municipality on the shores of Lake Geneva in the canton of Geneva, Switzerland, known for hosting several international organizations and diplomatic missions.
-
E.
BB-37
BB-37 is the hull number of USS Oklahoma, a Nevada-class battleship of the United States Navy that was sunk during the attack on Pearl Harbor in 1941.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biologic therapy
ⓘ
immunosuppressive agent ⓘ medication ⓘ monoclonal antibody ⓘ |
| administeredIn | infusion center ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| approvedForIndication |
inducing and maintaining clinical response in adults with Crohn’s disease
ⓘ
relapsing forms of multiple sclerosis in adults ⓘ |
| associatedWithRiskFactor | JC virus antibody positivity ⓘ |
| belongsToRegimenType | disease-modifying therapy for multiple sclerosis ⓘ |
| blackBoxWarningFor | progressive multifocal leukoencephalopathy ⓘ |
| canCause |
hepatotoxicity
ⓘ
hypersensitivity reactions ⓘ opportunistic infections ⓘ progressive multifocal leukoencephalopathy ⓘ |
| contraindicatedIn |
patients with a history of progressive multifocal leukoencephalopathy
ⓘ
patients with severely compromised immune systems ⓘ |
| developedBy |
Biogen
ⓘ
Elan Pharmaceuticals ⓘ |
| hasATCCode | L04AA23 ⓘ |
| hasDosingInterval | every 4 weeks ⓘ |
| hasDrugClass |
integrin inhibitor
ⓘ
selective adhesion-molecule inhibitor ⓘ |
| hasFormulation | concentrate for solution for infusion ⓘ |
| hasGenericName |
natalizumab
ⓘ
linked to:
Tysabri
|
| hasHalfLife | approximately 11 days ⓘ |
| hasMolecularType | humanized monoclonal antibody ⓘ |
| improves | disability outcomes in some patients with multiple sclerosis ⓘ |
| indicationRestriction |
generally reserved for Crohn’s disease patients who failed or are intolerant to conventional therapies
ⓘ
generally reserved for patients with inadequate response to other MS therapies ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isNotIndicatedFor |
pediatric multiple sclerosis in many regions
ⓘ
primary progressive multiple sclerosis ⓘ |
| isTradeNameOf |
natalizumab
ⓘ
linked to:
Tysabri
|
| mechanismOfAction |
blocks adhesion of leukocytes to vascular endothelium
ⓘ
reduces migration of immune cells into the central nervous system ⓘ |
| pregnancyCategory | may pose risk; use only if potential benefit justifies potential risk ⓘ |
| reduces |
formation of new MRI brain lesions in multiple sclerosis
ⓘ
relapse rate in relapsing multiple sclerosis ⓘ |
| requiresEnrollmentIn | risk management program for PML ⓘ |
| requiresMonitoring |
liver function tests
ⓘ
signs and symptoms of progressive multifocal leukoencephalopathy ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets | alpha-4 integrin ⓘ |
| usedFor |
Crohn’s disease
ⓘ
moderate to severe Crohn’s disease ⓘ relapsing forms of multiple sclerosis ⓘ relapsing-remitting multiple sclerosis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Tysabri Description of subject: Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
Referenced by (9)
Full triples — surface form annotated when it differs from this entity's canonical label.